10-Q quarterly report · filed Nov 5, 2026

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) Q3 2026 10-Q Quarterly Report

Short answer

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $41M (up 5.5% year over year) with net income of −$38M.

Q3 2026 key financials · XBRL

Revenue
$41M
+5.5% YoY · +4.0% QoQ
Net income
−$38M
+0.4% YoY · +15.4% QoQ
Operating margin
-91.2%
Gross margin
33.2%
EPS (diluted)
−$0.12
+0.0% YoY · +14.3% QoQ

Source: XBRL data from the PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) Q3 2026 10-Q on SEC EDGAR. USD.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $40.6M, up 6% YoY from $38.4M, driven by product revenue and services growth
  • Gross margin 33.2% vs 41.4% YoY, with gross profit down 15% to $13.5M
  • Instrument revenue up 16% to $13.9M, while consumables revenue declined 2% to $20.1M
  • Operating loss $37.0M, with operating margin negative 91.2% vs negative 101.1% YoY
  • Cash and investments $199.4M vs $279.5M at December 31, 2025; operating cash use $117.9M
  • Outlook: consumables growth expected, but funding constraints, memory costs and tariffs remain headwinds

Risk Factors

  • New asset-disposition risk: January 30, 2026 sale retained pre-closing liabilities tied to short-read sequencing technologies
  • New expense-reduction risk: third-quarter 2026 workforce reductions and development cuts may disrupt operations and produce higher-than-anticipated charges
  • Regulatory risk: BIOSECURE Act limits certain Chinese biotechnology equipment and services, potentially disrupting supply and commercialization
  • Near-term market risk: Revio and Vega adoption may lag as customers delay capital purchases amid uncertain academic and NIH funding
  • Financial risk: September 30, 2026 debt included $200.0 million due 2029 and $441.0 million due 2030 amid negative operating cash flow

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.